Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 17;14(16):3969.
doi: 10.3390/cancers14163969.

Current Evidence of a Deintensification Strategy for Patients with HPV-Related Oropharyngeal Cancer

Soo-Yoon Sung  1 , Yeon-Sil Kim  2 , Sung Hwan Kim  3 , Seung Jae Lee  4 , Sea-Won Lee  1 , Yoo-Kang Kwak  5
Affiliations
Review

Current Evidence of a Deintensification Strategy for Patients with HPV-Related Oropharyngeal Cancer

Soo-Yoon Sung et al. Cancers (Basel). .

Abstract

Human papillomavirus (HPV)-related oropharyngeal cancer differs from HPV-negative oropharyngeal cancer in terms of etiology, epidemiology, and prognosis. Younger and lower comorbidity patient demographics and favorable prognosis allow HPV-related oropharyngeal cancer patients to anticipate longer life expectancy. Reducing long-term toxicities has become an increasingly important issue. Treatment deintensification to reduce toxicities has been investigated in terms of many aspects, and the reduction of radiotherapy (RT) dose in definitive treatment, replacement of platinum-based chemotherapy with cetuximab, response-tailored dose prescription after induction chemotherapy, and reduction of adjuvant RT dose after transoral surgery have been evaluated. We performed a literature review of prospective trials of deintensification for HPV-related oropharyngeal cancer. In phase II trials, reduction of RT dose in definitive treatment showed comparable survival outcomes to historical results. Two phase III randomized trials reported inferior survival outcomes for cetuximab-based chemoradiation compared with cisplatin-based chemoradiation. In a randomized phase III trial investigating adjuvant RT, deintensified RT showed noninferior survival outcomes in patients without extranodal extension but worse survival in patients with extranodal extension. Optimal RT dosage and patient selection require confirmation in future studies. Although many phase II trials have reported promising outcomes, the results of phase III trials are needed to change the standard treatment. Since high-level evidence has not been established, current deintensification should only be performed as part of a clinical study with caution. Implementation in clinical practice should not be undertaken until evidence from phase III randomized trials is available.

Keywords: chemotherapy; de-escalation; deintensification; human papillomavirus; oropharyngeal cancer; p16; radiotherapy; transoral surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the literature search of deintensification trials.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., Kim E., Jiang B., Goodman M.T., Sibug-Saber M., Cozen W., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 2011;29:4294–4301. doi: 10.1200/JCO.2011.36.4596. - DOI - PMC - PubMed
    1. Cheng J., Zhou X., Xu H., Dan H., Li J., Chen Q. Incidence and Survival of Oral Cavity and Oropharyngeal Cancer in the United States From 1975 to 2018. J. Oral. Maxillofac. Surg. 2022;80:1294–1305. doi: 10.1016/j.joms.2022.03.015. - DOI - PubMed
    1. Damgacioglu H., Sonawane K., Zhu Y., Li R., Balasubramanian B.A., Lairson D.R., Giuliano A.R., Deshmukh A.A. Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001–2017. JAMA Otolaryngol. Head Neck Surg. 2022;148:155–165. doi: 10.1001/jamaoto.2021.3567. - DOI - PMC - PubMed
    1. Gillison M.L., Broutian T., Pickard R.K., Tong Z.Y., Xiao W., Kahle L., Graubard B.I., Chaturvedi A.K. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307:693–703. doi: 10.1001/jama.2012.101. - DOI - PMC - PubMed
    1. Ang K.K., Harris J., Wheeler R., Weber R., Rosenthal D.I., Nguyen-Tan P.F., Westra W.H., Chung C.H., Jordan R.C., Lu C., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 2010;363:24–35. doi: 10.1056/NEJMoa0912217. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources